Trial · NCT00467987

Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism

NCT00467987, Not applicable, Terminated, University at Buffalo; results first posted 2024-02-06

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism. Trials, record NCT00467987. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00467987

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Effect of Androgel on Atherogenesis in Type 2 Diabetic Males With Hypogonadotrophic Hypogonadism
NCT number: NCT00467987
Status: Terminated
Phases: Not applicable
Enrollment: 47 participants, actual
Lead sponsor: University at Buffalo
Conditions: Type 2 Diabetic Male With Hypogonadotrophic Hypogonadism
Interventions: androgel, placebo
First posted: 2007-05-01
Last updated: 2024-02-06
Results first posted: 2024-02-06

Source ClinicalTrials.gov

Registered outcomes2

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Carotid Intima Media Thickness	2 years	carotid intima media thickness measured at baseline 0 months and at 2 years in centimeters (cm).
Secondary	Endothelial Function	2 years	assessed by brachial artery Flow mediated dilatation (FMD in Centimeters)

Source ClinicalTrials.gov

Outcomes2

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Carotid Intima Media Thickness	2 years	the no treatment group measurement was collected only at baseline and not followed beyond that point	centimeters (cm)	MEAN
SECONDARY	Endothelial Function	2 years	the no treatment group was not followed beyond baseline so no 2 years data will be entered.	centimeters (cm)	MEAN

Source ClinicalTrials.gov

Results by group10

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Carotid Intima Media Thickness	Androgel	0 months	0.632	Standard Deviation 0.115	centimeters (cm)
Carotid Intima Media Thickness	Placebo	0 months	0.590	Standard Deviation 0.127	centimeters (cm)
Carotid Intima Media Thickness	no Treatment	0 months	0.595	Standard Deviation 0.190	centimeters (cm)
Carotid Intima Media Thickness	Androgel	2 years	0.695	Standard Deviation 0.214	centimeters (cm)
Carotid Intima Media Thickness	Placebo	2 years	0.580	Standard Deviation 0.133	centimeters (cm)
Endothelial Function	Androgel	0 months	0.469	Standard Deviation 0.054	centimeters (cm)
Endothelial Function	Placebo	0 months	0.523	Standard Deviation 0.119	centimeters (cm)
Endothelial Function	no Treatment	0 months	0.474	Standard Deviation 0.087	centimeters (cm)
Endothelial Function	Androgel	2 years	0.440	Standard Deviation 0.109	centimeters (cm)
Endothelial Function	Placebo	2 years	0.483	Standard Deviation 0.106	centimeters (cm)

Source ClinicalTrials.gov

Participant flow9

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Androgel	13
Overall Study	STARTED	Placebo	12
Overall Study	STARTED	no Treatment	22
Overall Study	COMPLETED	Androgel	10
Overall Study	COMPLETED	Placebo	10
Overall Study	COMPLETED	no Treatment	22
Overall Study	NOT COMPLETED	Androgel	3
Overall Study	NOT COMPLETED	Placebo	2
Overall Study	NOT COMPLETED	no Treatment	0

Source ClinicalTrials.gov

Adverse events0

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

None in this release.

Adverse event totals9

The totals the trial posted for each group.

Total	Group	At risk
Total, all-cause mortality	Androgel	10
Total, all-cause mortality	Placebo	10
Total, all-cause mortality	no Treatment	22
Total, other adverse events	Androgel	10
Total, other adverse events	Placebo	10
Total, other adverse events	no Treatment	22
Total, serious adverse events	Androgel	10
Total, serious adverse events	Placebo	10
Total, serious adverse events	no Treatment	22

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00467987

GET https://conductscience.org/api/trials/v1/NCT00467987/registered

API reference For AI assistants